BioModels, a Boston-based preclinical Contract Research Organization (CRO), has consistently provided our biotech, pharmaceutical, and academic clients with expertly conducted and highly translational rodent disease models since our inception in 1997. Our scientific expertise spans the fields of immunology/inflammation, with expertise in IBD, as well as cancer supportive care, pulmonary disease, fibrosis, oncology, and many other indications. We’ve conducted studies in collaboration with more than 300 unique companies over the past decade. Many of the world’s most respected biotech and pharmaceutical companies regularly rely on BioModels’ expertise and efficiency to conduct their outsourced preclinical research.
We view our clients as collaborators rather than customers. The result is an active engagement in personal service and scientific discussions to develop and execute your studies. At BioModels, you will work with a PhD level scientist who is an expert in your selected disease indication. Your scientific partner will be your primary resource to assist in study design, monitor quality control, and provide timely updates on study progress, allowing for real time decisions that often result in improved study outcomes.
Customized animal models are often needed to keep pace with the ever-changing landscape of medicine and science. BioModels specializes in the development of custom disease models to accommodate novel therapeutics and disease indications for which the current animal models are insufficient or do not exist. For our clients, this results in successful preliminary testing of compounds in emerging (or understudied) therapeutic areas, mechanism of action studies, and the identification of novel molecular biomarkers of disease.
Core to the BioModels mission is to provide clinically relevant and highly translational models of human diseases. Providing this distinctive service at a consistently high level of quality is made possible by the unique blend of professionals comprising the BioModels team. The combination of skill-sets produce an efficient team with a track record of enabling well over 100 novel therapeutics to move from test tube to patients.
BioModels has earned accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) for upholding the highest standards in animal use and care. BioModels is compliant with all U.S. Department of Agriculture (USDA) standards. BioModels is compliant with all Office of Laboratory Animal Welfare (OLAW) policies and guidelines.
BioModels provides a start-to-finish solution that takes you from initial inquiry to study execution and data delivery. Our collaborative approach allows us to combine your study needs and our expertise to design and conduct a study that yields accurate and actionable data.
Initial Inquiry: By filling out the contact us form, our Business Development Manager will contact you withing 1 business day to provide you with any additional information requested as well as an introduction to a Scientist on our team.
Concept & Consultation: Our expert scientists will then set up a meeting to discuss our capabilities in the context of your specific project goals and your science. This is often the catalyst for getting a CDA in place.
Study Design: Based on your unique project goals/needs, we will create a customized study plan and quote that outlines all of your study specifics (disease model, number of animals/groups, dosing route/schedule, endpoints, samples collections, etc).
Services Agreement & Work Order: Once a study design is finalized, we generate formal services agreements that will be reviewed and signed by both parties.
Study Initiation & Data Updates: Upon receipt of signed study agreements, the project will be scheduled (typically starting within 3-4 weeks), and we will execute the project. Along the way, your lead scientist will always be available to provide data updates and answer any questions that may arise during the project progression.
Data Analyses & Final Report: Upon completion of the study, your lead scientist will provide you with a final data update and an informal overview of the results. This often spawns additional discussion and potentially the addition of other endpoints from the samples collected. Upon completion of all work and review of all data, we will issue a comprehensive draft and final report of the study result
BioModels was founded in 1997 by Dr. Edward Fey, Dr. Stephen T. Sonis, and Harry Barnett. Drs. Fey and Sonis, both employees of Brigham and Women’s Hospital at the time, recognized that there was a critical need for access to highly translational disease models to de-risk biotech/pharmaceutical companies’ transition from the laboratory to the clinic. They also realized that many of the models used by Brigham investigators could be adapted for drug development and modified to focus on clinical endpoints. In collaboration with the Brigham, and using models developed by Dr. Stephen Sonis for the study of oral mucositis as a prototype, the company was started.
As the company has grown over the past 25+ years, BioModels has expanded its personnel, space, and expertise. In 2012 Daniel Lichtman joined BioModels as Managing Partner and shortly thereafter, then Director of Research Dr. Gregory D. Lyng also became a partner. After more than a decade in Watertown, MA, BioModels moved to its current location in Waltham, MA in 2019. The new location’s 25,000+ square feet allowed for the development of a purpose-built facility to support multiple vivarium’s, procedure rooms, surgical suites as well as in vitro spaces to support cell culture, microbiology, and our ever-expanding selection of assays/technology. Our AALAC accredited state-of-the-art facility enhances our ability to continue to develop a wide range of models in immunology/inflammatory disease, cancer supportive care, oncology, pulmonary, fibrosis, metabolic diseases, among many other indications. Our location makes it easy for companies in the Boston area to work with us an extension of their labs, coming in to observe procedures, picking up fresh samples, or providing us with fresh materials/test articles that are necessary for their projects.
Founder, Partner,
Chief Scientific Ocer
Managing Partner
Founder, Partner,
Chief Scientific Ocer
Founder, Partner,
Chief Scientific Ocer
Founder, Partner,
Chief Scientific Ocer
Founder, Partner,
Chief Scientific Officer
Founder, Partner,
Chief Scientific Officer